Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2370-2377

  Fineman, Mark S ^b   Bicsak, Thomas A ^b   Shen, Larry Z ^b   Taylor, Kristin ^b   Gaines, Eling ^b   Varns, Amanda ^b   Kim, Dennis ^b   Baron, Alain D ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; EXENDIN 4; FRUCTOSAMINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSAMINE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; VENOMS;

EID: 0037850667     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2370     Document Type: Article

References (37)

1. American Diabetes Association: Postprandial blood glucose. Diabetes Care 24:775-778, 2001
2. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
3. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
4. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
5. Mudaliar S, Edelman SV: Insulin therapy in type 2 diabetes. Endocrinol Metabol Clinics N Am 30:935-982, 2001
6. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, UKPDS Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). 25:330-336, 2002
7. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
8. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372, 2002
9. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (macaca mulatta). Diabetes 48:1026-1034, 1999
10. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589, 2001
11. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290, 2002
12. Gedulin B, Jodka C, Hoyt J: Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats (Abstract). Diabetes 48 (Suppl. 1):A199, 1999
13. Jodka C, Gedulin B, Young A: Exendin-4 potently regulates gastric emptying in rats (Abstract). Diabetes 47 (Suppl. 1):403A, 1998
14. Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24:371-381, 2001
15. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655, 1993
16. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
17. Tourrel C, Bailbé D, Meile M-J, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570, 2001
18. Tourrel C, Bailbé D, Lacorne M, Meile MJ, Kergoat M, Portha B: Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-1452, 2002
19. Bhavsar S, Watkins J, Young A: Comparison of central and peripheral effects of exendin-4 and GLP-1 on food intake in rats (Abstract). In Program and Abstracts: 80th Annual Meeting of the Endocrine Society. Bethesda, MD, The Endocrine Society, 1998, p. 433
20. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinol 141:1936-1941, 2000
21. Johnson RN, Metcalf PA, Baker JR: Fructosamine: A new approach to the estimation of serum glycosylprotein: an index of diabetic control. Clin Chim Acta 127:87-95, 1983
22. The DCCT Research Group: Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 33:2267-2271, 1987
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
24. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio heart study. Diabetes Care 20:1087-1092, 1997
25. Young A, Blase E, Petrella E, Seward M: Exendin-4 is a circulating meal-related peptide in the Gila monster (Heloderma suspectum) (Abstract). Diabetes 48 (Suppl. 1):A425, 1999
26. Chen YE, Drucker D: Tissue-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 272:4108-4115, 1997
27. Drucker DJ: Glucagon-like peptides. Diabetes 47:159-169, 1998
28. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50, 1999
29. Gedulin B, Lawler R, Jodka C, Young A: Amylin inhibits pentagastrin-stimulated gastric acid secretion: comparison with glucagon-like peptide-1 and exendin-4 (Abstract). Diabetes 46 (Suppl. 1):188A, 1997
30. Nishizawa H, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K: The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80:14-21, 2000
31. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S33-S49, 2002
32. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
33. Turner RC, Cull CA, Frighi V, Holman RR, UKPDS Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
34. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 280:140-146, 1998
35. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4: reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers: Am J Physiol Endocrinol Metab 281:E155-E161, 2001
36. Kolterman O, Gottlieb A, Gaines E, Fineman M: Five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes reduces postprandial glucose, glucagon and triglyceride concentrations (Abstract). Diabetologia 43 (Suppl. 1): A189, 2000
37. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404, 1998